From: Cerebral palsy in Moldova: subtypes, severity and associated impairments
Estimated GMFCS | Estimated BFMF | |||||||
---|---|---|---|---|---|---|---|---|
I-II N (%) | III N (%) | IV-V N (%) | Total N (%) | I-II N (%) | III N (%) | IV-V N (%) | Total N (%) | |
GA | ||||||||
GA < 28 weeks | 1 (2) | 5 (9) | 5 (7) | 11 (6) | 4 (6) | 3 (6) | 4 (6) | 11 (6) |
GA 28–31 weeks | 0 | 7 (13) | 5 (7) | 12 (7) | 1 (1) | 7 (15) | 4 (6) | 12 (7) |
GA 32–36 weeks | 11 (18) | 11 (21) | 7 (10) | 29 (15) | 14 (19) | 9 (19) | 6 (10) | 29 (15) |
GA > 37 weeks | 48 (80) | 30 (57) | 55 (76) | 133 (72) | 54 (74) | 28 (60) | 51 (78) | 133 (72) |
BW | ||||||||
BW < 1000 g | 1 (2) | 3 (6) | 2 (3) | 6 (3) | 3 (4) | 1 (1) | 2 (3) | 6 (3) |
BW 1000-1499 g | 2 (3) | 4 (7) | 5 (7) | 11 (6) | 3 (4) | 4 (9) | 4 (6) | 11 (6) |
BW 1500-2499 g | 10 (17) | 12 (23) | 16 (22) | 38 (21) | 12 (17) | 13 (28) | 13 (20) | 38 (21) |
BW > 2500 g | 47 (78) | 34 (64) | 49 (68) | 130 (70) | 55 (75) | 29 (62) | 46 (71) | 130 (70) |
Apgar (1 min) | ||||||||
Apgar 0–3 | 1 (1) | 7 (13) | 15 (21) | 23 (13) | 3 (5) | 7 (15) | 13 (20) | 23 (13) |
Apgar 4–6 | 16 (27) | 16 (30) | 24 (33) | 56 (30) | 20 (27) | 16 (34) | 20 (31) | 56 (30) |
Apgar 7–10 | 43 (72) | 30 (57) | 33 (46) | 106 (57) | 50 (68) | 24 (51) | 32 (49) | 106 (57) |
Apgar (5 min) | ||||||||
Apgar 0–3 | 1 (2) | 3 (5) | 7 (10) | 11 (6) | 1 (2) | 4 (9) | 6 (9) | 11 (6) |
Apgar 4–6 | 6 (10) | 11 (21) | 18 (25) | 35 (19) | 9 (12) | 10 (21) | 16 (25) | 35 (19) |
Apgar 7–10 | 53 (88) | 39 (74) | 47 (65) | 139 (75) | 63 (86) | 33 (70) | 43 (66) | 139 (75) |
Total | 60 (100) | 53 (100) | 72 (100) | 185 (100) | 73 (100) | 47 (100) | 65 (100) | 185 (100) |